ID   BHP 5-16
AC   CVCL_6284
SY   BHP5-16; BHP-5
DR   EFO; EFO_0022673
DR   BioSample; SAMN03151829
DR   cancercelllines; CVCL_6284
DR   Cosmic; 1005447
DR   Cosmic; 1094765
DR   Wikidata; Q54796503
RX   PubMed=8675585;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland papillary carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00183.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 13,17
ST   D21S11: 30
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 29
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis, Amanda
RA   Theodosopoulos, George
RA   Atkin, Isobel
RA   Drexler, Hans Gunther
RA   Kohara, Arihiro
RA   MacLeod, Roderick A.F.
RA   Masters, John R.W.
RA   Nakamura, Yukio
RA   Reid, Yvonne A.
RA   Reddel, Roger Robert
RA   Freshney, Robert Ian
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao, Mei
RA   Sano, Daisuke
RA   Pickering, Curtis R.
RA   Jasser, Samar A.
RA   Henderson, Ying C.
RA   Clayman, Gary L.
RA   Sturgis, Erich M.
RA   Ow, Thomas J.
RA   Lotan, Reuben
RA   Carey, Thomas E.
RA   Sacks, Peter G.
RA   Grandis, Jennifer Rubin
RA   Sidransky, David
RA   Heldin, Nils-Erik
RA   Myers, Jeffrey N.
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe, Rebecca E.
RA   Klopper, Joshua Paul
RA   Korch, Christopher T.
RA   Pugazhenthi, Umarani
RA   Benezra, Miriam
RA   Knauf, Jeffrey A.
RA   Fagin, James Alexander
RA   Marlow, Laura A.
RA   Copland, John Alton 3rd
RA   Smallridge, Robert Christian
RA   Haugen, Bryan R.
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=8675585; DOI=10.1210/jcem.81.7.8675585;
RA   Ohta, Kazuyasu
RA   Pang, Xuan-Ping
RA   Berg, Loretta
RA   Hershman, Jerome Marshall
RT   "Antitumor actions of cytokines on new human papillary thyroid
RT   carcinoma cell lines.";
RL   J. Clin. Endocrinol. Metab. 81:2607-2612(1996).
//